secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2025-09-23T23:59:59+00:00
Accession:  0001193125-25-213332
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion licenses MIT tech for treatment-resistant depression; relaunches as neuropsychiatry company
--------------------------------------------------------------------------------

- Entered exclusive worldwide license with MIT for neuropsychiatric technology; upfront payment nominal, milestones up to $4.4M plus low single-digit royalties.
- Lead program targets 3M Americans with treatment-resistant depression (TRD); Phase 2 proof-of-concept trial expected to start 2026 with data in 2027.
- Company relaunches as innovation-driven neuropsychiatry firm, led by world-class team in neuropsychiatry, anesthesiology, and machine learning.
- Expanding pipeline beyond TRD; exploring therapies for other neuropsychiatric diseases with large unmet needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/0001193125-25-213332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312525213332/d51498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-213332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer